Wire open Last filed CagriSema REDEFINE 9 lower doses cut weight by about 21 percent in Phase 3 trial RSS
Peptide Zone

Peptide medicine news,
filed as it happens.

Morning wire
UrgentREGNews

Mounjaro Health Canada approval adds heart risk indication in type 2 diabetes

Health Canada cleared tirzepatide to lower the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes and heart disease. The trial behind it showed non inferiority to dulaglutide, not superiority.

Editorial illustration for the story: Mounjaro Health Canada approval adds heart risk indication in type 2 diabetes
Illustration: Peptide Zone. Editorial drawing, not data.

What's new

Health Canada approved Mounjaro to lower major cardiovascular event risk in adults with type 2 diabetes and established heart disease, and authorized the Foundayo pill on 13 November.

Why it matters

Tirzepatide now carries a heart outcome claim in Canada, though SURPASS CVOT showed only that it was not inferior to dulaglutide.

What's next

Lilly expects Foundayo in Canadian pharmacies in January. Drug plan coverage for the new Mounjaro use has not been announced.

Health Canada has approved Mounjaro to lower the risk of major cardiovascular events in adults with type 2 diabetes and established heart disease, Eli Lilly Canada said on 18 November. The Mounjaro Health Canada approval rests on SURPASS CVOT, a head to head outcomes trial against another incretin drug rather than placebo. Five days earlier the regulator also authorized Foundayo, Lilly's daily GLP 1 pill, for weight management. Lilly expects the pill in Canadian pharmacies in January.

What Health Canada approved for Mounjaro

Health Canada issued a Notice of Compliance for the new use, according to the company release. The indication covers adults with type 2 diabetes and established cardiovascular disease and aims to lower the risk of major adverse cardiovascular events, defined as cardiovascular death, non fatal heart attack and non fatal stroke. Mounjaro, the brand name for tirzepatide, is a single peptide that acts on both the GIP and GLP 1 hormone receptors and is given as a weekly injection. Before this decision it was approved in Canada only to improve blood sugar control, as an add on to diet and exercise, in adults and in children aged 10 and older with type 2 diabetes. The approval adds a heart outcome to that label but does not change who can receive the drug.

Lilly framed the decision as a broader role for the drug. "This new cardiovascular indication for Mounjaro builds on its established benefits," said Mathilde Merlet, general manager and president of Lilly Canada, in the release. Jeffrey Habert, an assistant professor of family and community medicine at the University of Toronto quoted by the company, said that "managing type 2 diabetes today means looking beyond A1C." The company cites earlier research suggesting that about one third of people with type 2 diabetes also have cardiovascular disease. The release does not say whether provincial drug plans or private insurers will change their coverage of Mounjaro for this use, and it gives no date for an updated product monograph.

SURPASS CVOT tested tirzepatide against dulaglutide

SURPASS CVOT enrolled more than 13,000 adults with type 2 diabetes and high cardiovascular risk in 30 countries, including Canada, and followed them for more than four and a half years, according to Lilly. Unlike most outcome trials of diabetes drugs, it did not use a placebo. Its comparator was dulaglutide, sold as Trulicity, a GLP 1 drug that already carries a cardiovascular benefit on its label. Lilly reports that tirzepatide met the goal of non inferiority, with an 8% lower rate of the three part outcome of cardiovascular death, heart attack or stroke. The estimated hazard ratio was 0.92, with a 95.3% confidence interval of 0.83 to 1.01, the release states.

Because that interval crosses 1.0, the trial shows tirzepatide was not worse than dulaglutide but did not prove it was better.

The detail matters for how the result is read. Because that interval crosses 1.0, the trial shows tirzepatide was not worse than dulaglutide but did not prove it was better. Lilly's description of an 8% lower rate is the point estimate, not a confirmed difference. Harpreet Bajaj, the Canadian national lead investigator for the trial, called the new indication "an important step forward in how we can improve care for people living with type 2 diabetes," in the company release. The most common side effects were gastrointestinal, generally mild to moderate, and mostly seen while the dose was being raised, Lilly said. The full Lilly Canada announcement sets out the trial design.

DateProductHealth Canada decision
13 Nov 2026Foundayo, orforglipronAuthorized for weight management in eligible adults and for type 2 diabetes
18 Nov 2026Mounjaro, tirzepatideNew indication to lower major cardiovascular event risk in type 2 diabetes with heart disease
PendingWegovy pill, oral semaglutideStill awaiting a decision, per The Canadian Press

Foundayo authorized for weight management in Canada

Health Canada authorized Foundayo on 13 November, The Canadian Press reported. Its active ingredient, orforglipron, acts on the GLP 1 receptor but is a small molecule rather than a peptide, which lets it be taken as a daily pill. It is approved for adults with obesity and for overweight adults with at least one weight related condition, such as high blood pressure or sleep apnea, and also for type 2 diabetes. Lilly spokesperson Ethan Pigott said the company expects the pills in Canadian pharmacies in January. In the United States, Lilly has reported that Foundayo sales missed forecasts even as demand grew. The Canadian report gave no price and no information on insurance coverage for the pill.

The Canadian authorization also changes the oral options in the country. Novo Nordisk's Rybelsus, an oral form of semaglutide, is sold in Canada for type 2 diabetes only, while the Wegovy pill is still awaiting a Health Canada decision, according to the same report. Vancouver endocrinologist Ehud Ur, who is not linked to either company, told a Canadian Press reporter that the choice to prescribe the pill would depend on the patient. He said he is still waiting for trial results on whether orforglipron lowers cardiovascular risk, a benefit that semaglutide and tirzepatide have shown in outcome studies. That gap is the main clinical difference between the two Lilly decisions this month.

What the Mounjaro Health Canada approval means next

For doctors, the Mounjaro Health Canada approval adds a second incretin option with an outcome claim for patients with diabetes and heart disease, alongside dulaglutide and semaglutide. It does not cover people with obesity who do not have diabetes. Coverage decisions by public and private drug plans will shape how widely the indication is used, and none were announced. The approval follows other regulatory advice on tirzepatide this month, including EMA advice on oral contraceptives during dose escalation. Lilly reported third quarter revenue growth of 39%, driven largely by tirzepatide, and the company's share price fell for four straight days this week during a broad market sell off, according to market reports.

For Foundayo, the open questions are supply and evidence. Lilly has given only a January timeframe for pharmacy availability, and no outcome trial result for orforglipron has been published. Canadians who want these medicines should get them through a prescriber and a licensed pharmacy. Products sold online as tirzepatide or orforglipron without a prescription are not approved by Health Canada, and their content cannot be checked. Further approvals and label changes for peptide and incretin medicines appear on the regulators desk as agencies publish them. Health Canada's product monograph for the new Mounjaro indication, once posted, will give the label wording in full.

Conclusion

The Mounjaro Health Canada approval gives tirzepatide a heart outcome indication for adults with type 2 diabetes and established cardiovascular disease, based on a trial that showed it was not inferior to dulaglutide. It did not prove superiority. Alongside it, Foundayo became the first oral GLP 1 drug authorized for weight management in Canada, with pharmacy supply expected in January and its cardiovascular effect still unknown.

More from the wire

Same thread first, then the same desk.